Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3390 studies found for:    non-Hodgkin's lymphoma
Show Display Options
RSS Create an RSS feed from your search for:
non-Hodgkin's lymphoma
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab
2 Completed Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: bendamustine hydrochloride
3 Completed Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America
Conditions: Multiple Myeloma;   Leukemia;   Lymphoid;   Lymphoma;   Non-Hodgkin
Interventions: Other: Chronic Lymphocytic Leukemia (CLL);   Other: Multiple Myeloma (MM);   Other: Non-Hodgkin's lymphoma (NHL)
4 Active, not recruiting A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Bendamustine;   Drug: Rituximab
5 Recruiting To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma, Burkitt's
Intervention: Drug: Tenofovir
6 Completed A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Everolmus
7 Completed SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bendamustine and rituximab
8 Active, not recruiting An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Rituximab
9 Completed
Has Results
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Oxaliplatin
10 Completed Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era
Condition: Non-Hodgkin's Lymphoma
Intervention:
11 Completed
Has Results
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bortezomib + Rituximab;   Drug: Rituximab
12 Unknown  Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bortezomib, tositumomab
13 Completed Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention:
14 Withdrawn A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
Condition: Relapsed/Refractory Non-Hodgkin's Lymphoma
Intervention: Drug: [14C]ABT-199 (GDC-0199)
15 Recruiting Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents
Condition: Non-Hodgkin Lymphoma
Intervention: Device: PET / CT
16 Completed Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: SDX-105
17 Recruiting A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Condition: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Interventions: Drug: Imprime PGG;   Drug: Rituximab
18 Recruiting Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Lenalidomide/Rituximab
19 Active, not recruiting Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide
20 Completed
Has Results
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Conditions: Low-grade B Cell Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Interventions: Drug: SyB L-0501;   Drug: rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.